The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies. (Q40451304)

From Wikidata

Jump to navigation Jump to search

scientific article published on February 2005

Language	Label	Description	Also known as
English	The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies.	scientific article published on February 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

The epidemiological contribution to the preparation of field trials for HIV and STI vaccines: objectives and methods of feasibility studies. (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Massimo Ciccozzi

object named as

Massimo Ciccozzi

3

0 references

4

object named as

Giovanni Rezza

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

author name string

Barbara Suligoi

1

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Theresa M Wagner

2

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

language of work or name

0 references

publication date

1 February 2005

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

23

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

1437-1445

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

Vaccine efficacy trials for human immunodeficiency virus/acquired immunodeficiency syndrome are feasible in the United States: a commentary on the HIVNET Vaccine Preparedness Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Trends in HIV-1 incidence in a cohort of prostitutes in Kenya: implications for HIV-1 vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Performance characteristics of the immunoglobulin G-capture BED-enzyme immunoassay, an assay to detect recent human immunodeficiency virus type 1 seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Large-scale efficacy trials of hepatitis B vaccines in the USA: Baseline data and protocols

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Assessment of the changing willingness to participate in phase III HIV vaccine trials among men who have sex with men.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Who will enroll? Predicting participation in a phase II AIDS vaccine trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Determinants of enrollment in a preventive HIV vaccine trial: hypothetical versus actual willingness and barriers to participation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Challenges in the conduct of vaginal microbicide effectiveness trials in the developing world

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Practical experiences in obtaining informed consent for a vaccine trial in rural Africa.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Vaccine characteristics and acceptability of HIV immunization among adolescents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

HIV vaccine fails in phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Thailand Beats the Odds in Completing Vaccine Test

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Thailand's Prime-Boost HIV Vaccine Phase III.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Feasibility of human immunodeficiency virus vaccine trials in homosexual men in the United States: risk behavior, seroincidence, and willingness to participate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Feasibility and suitability of targeting young gay men for HIV vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Willingness to participate in HIV vaccine trials among men who have sex with men in Rio de Janeiro, Brazil. Projeto Praça Onze Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Recruitment, screening and characteristics of injection drug users participating in the AIDSVAX®B/E HIV vaccine trial, Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Dropouts in a long-term follow-up study involving voluntary counseling and HIV testing: experience from a cohort of police officers in Dar Es Salaam, Tanzania

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Design, implementation, and evaluation at entry of a prospective cohort study of homosexual and bisexual HIV-1-negative men in Belo Horizonte, Brazil: Project Horizonte

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Continued high HIV-1 incidence in a vaccine trial preparatory cohort of injection drug users in Bangkok, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Feasibility of a preventive HIV-1 vaccine cohort among persons attending sexually transmitted disease clinics in Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

On the role of sexual behavior in the spread of hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Virologic characteristics of subclinical and symptomatic genital herpes infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Prospects for control of herpes simplex virus disease through immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

The burden of infection with HSV-1 and HSV-2 in England and Wales: implications for the changing epidemiology of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Once-daily valacyclovir to reduce the risk of transmission of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

The acquisition of herpes simplex virus during pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Attitudes regarding vaccinations of STDs and other diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Prerequisites for human papillomavirus vaccine trial: results of feasibility studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

A prospective study of the relationship between prediagnostic human papillomavirus seropositivity and HPV DNA in subsequent cervical carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Attitudes of adolescent/young adult women toward human papillomavirus vaccination and clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

Willingness to participate in AIDS vaccine trials among high-risk populations in northern Thailand

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.10.002

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.10.002

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40451304&oldid=1493976317"